Outcome of Board Meeting

Ref: AHCL/2026-27/C053 November 05, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai – 400 051 Scrip Code – 544350 Symbol : AGARWALEYE Dear Sir / Madam, Sub: Corrigendum to Outcome of the Board Meeting held on November 05, 2026 Ref: Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) This is with reference to our earlier communication dated November 05, 2026, regarding the Outcome of the Board Meeting held today, i.e., November 05, 2026. We hereby inform you that due to an inadvertent clerical error in the notes section of the Standalone and Consolidated Financial Results submitted along with the erstwhile outcome letter, a corrigendum is being issued to rectify the same. Except for the aforesaid modification in the notes section of the Standalone and Consolidated Financial Results, all other contents of the earlier outcome submission, including the Limited Review Reports and the appointment & redesignation of Dr. Amar Agarwal, Chairman and Non-Executive Director of the Company, as the Executive Chairman (Whole-Time Director) of the Company shall remain intact and unchanged. The corrected Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026, are enclosed herewith for your records and information. We request you to kindly take the above on record. For Dr. Agarwal’s Health Care Limited Thanikainathan Arumugam Company Secretary and Compliance Officer Encl.: as above. DR. AGARWAL'S HEALTH CARE LIMITED Registered Office: 6th Floor, Menon Eternity, 1st Main Road, Austin Nagar, Alwarpet, Chennai -600 018. Tel: +91 44 4378 7777 I CIN: L85100TN2010PLC075403 I CST No: 33AADCD4418MlZO Email: info@dragarwal.com I Website: www.dragarwals.co.in S.R. LLP BATLIBOI & ASSOCIATES 10th Floor, Tidel Park "A" Block, North Wing Chartered Accountants No. 4, Rajiv Gandhi Salai Taramani, Chennai -600 113 India Tel: +9144 6117 9000 Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Dr. Agarwal's Health Care Limited 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Dr. Agarwal's Health Care Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended September 30, 2026, and year to date from April 01, 2026, to September 30, 2026, (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). 2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors . Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable. 4. The Statement includes the results of the following entities· S. No. Name of the Entity Relationship 1 Dr. Agarwal's Health Care Limited Holding Company 2 Dr. Thind Eve Care Private Limited Subsidiary 3 Aditva Jyot Eye Hospital Private Limited Subsidiary 4 Elisar Life Sciences Private Limited Subsidiary 5 Orbit Healthcare Services (Mauritius) Limited* Subsidiary *Subsidiaries of Orbit Healthcare Services (Mauritius) Limited i) Orbit Healthcare Services (Tanzania) Limited Step-down Subsidiary ii) Orbit Healthcare Services (Ghana) Limited Step-down Subsidiary iii) Orbit Health Care Services (Kenya) Limited Step-down Subsidiary iv) Orbit Healthcare Services Mozambique Limitada Step-down Subsidiary V) Orbit Healthcare Services Madagascar SARL Step-down Subsidiary vi) Orbit Health Care Services (UQanda) Limited Step-down Subsidiary vii) Orbit Health Care Services (Zambia) Limited Step-down Subsidiary viii) Orbit Health Care Services Limited, Rwanda Step-down Subsidiary ix) Orbit Health Care ETH PLC (Ethiopia) Step-down Subsidiary (w.e.f. May 26, 2026) x) Orbit Health Care Services Nigeria Limited Step-down Subsidiary (w.e.f September 29, 2026) S.R. Bat/iboi & Associates LLP, a Limited Liability Partnership with LLP Identity No. AAB·4295 Regd, Office: 22. Camac Street, Block 'B', 3rd Floor, Kolkata· 700 □16 S.R. LLP BATL/80/ & ASSOCIATES Chartered Accountants 5. Based on our review conducted and procedures performed as stated in Paragraph 3 above and based on the consideration of the review reports of other auditors referred to in Paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. The accompanying Statement includes the unaudited Interim financial results and other financial information, in respect of two subsidiaries and unaudited Consolidated Interim financial results and other financial information of one subsidiary (including ten step-down subsidiaries) whose unaudited Interim financial results include total assets of Rs. 299.27 crores as at September 30, 2026, total revenues of Rs. 75.14 crores and 142.93 crores, total net profit after tax of Rs. 8.51 crores and Rs. 16.12 crores, total comprehensive income of Rs. 8.50 crores and Rs. 15.97 crores, for the quarter ended September 30, 2026, and period ended that date, respectively, and net cash outflow of Rs. 1.58 crores for the period ended September 30, 2026, as considered in the Statement which have been reviewed by their respective independent auditors. The independent auditor's reports on unaudited interim financial results of these entities have been furnished to us by the Management [Showing first 8,000 characters — download PDF for full document]